Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Vikas Lifecare Ltd

| Unaudited Consolidated Financial Results Q2 & H1 FY 2025-26

Report Source

⬤21st Apr 26

Summary : Vikas Lifecare Limited reported mixed financial results with significant consolidated losses, while navigating complex regulatory approvals and tax evaluations for key investments.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Standalone Half Year (Sep 30, 2025): 23,994.14 Lakhs
  2. Consolidated Half Year (Sep 30, 2025): 24,608.45 Lakhs
  3. Key expenses: Cost of Materials, Purchases, Employee Benefits, Finance Costs
  4. Standalone Half Year (Sep 30, 2025): 22,966.97 Lakhs
  5. Consolidated Half Year (Sep 30, 2025): 23,371.02 Lakhs
  6. Segment-wise: Polymers, Agro, Infrastructure, Gas Meter, Real Estate
  7. Standalone Net cash from operations (Sep 30, 2025): 40,109.79 Lakhs
  8. Standalone Net cash used in investing (Sep 30, 2025): (42,530.69) Lakhs
  9. Consolidated Net cash from operations (Sep 30, 2025): 40,598.06 Lakhs
  10. Consolidated Net cash used in investing (Sep 30, 2025): (42,223.61) Lakhs
  11. Standalone Total Assets (Sep 30, 2025): 80,523.63 Lakhs
  12. Consolidated Total Assets (Sep 30, 2025): 73,128.45 Lakhs
  13. Significant investments in non-current assets
  14. Entered into during half year ended Sep 30, 2025
  15. Requires prior shareholder approval, not yet obtained
  16. Both standalone and consolidated results presented
  17. Consolidated includes subsidiaries and associates

Corporate Overview

  1. Domestic
  2. Export: Ghana
  3. Export: Nepal
  4. Export: Benin
  5. Export: Mauritius
  6. Export: Bangladesh
  7. Export: UAE
  8. Export: China
  9. Obtaining shareholder approval for related party transactions
  10. Securing regulatory approvals for IGL Genesis investment
  11. Evaluating tax implications of Ebix settlement
  12. Reliance on related party transactions
  13. Investment in Ebix International Holdings Limited (Associate)
  14. Investment in IGL Genesis Technologies Limited
  15. Trading and Manufacturing Division - Agro
  16. Trading and Manufacturing Division - Polymers
  17. Trading Division - Infrastructure
  18. Trading Division - Gas Meter
  19. Real estate Division
  20. Factual and compliance-oriented
  21. Addressing regulatory requirements and approvals
  22. Major customers in Trading & Manufacturing Division - Agro
  23. Trading and Manufacturing Division - Polymers
  24. Trading and Manufacturing Division - Agro
  25. Trading and Manufacturing Division - Infrastructure
  26. Trading Division - Gas Meter
  27. Real estate Division

Risk Factors

  1. Unapproved related party transactions
  2. Pending IGL Genesis investment approvals
  3. Uncertain Ebix settlement tax impact
  4. Significant consolidated financial losses

Key Drivers

  1. Resolving IGL Genesis investment approvals
  2. Favorable Ebix tax implication outcome
  3. Shareholder approval for related party deals
  4. Improved performance in Agro and Polymers

Auditor’s Report

  1. Unmodified review report
  2. Ebix Inc. acquisition and settlement details
  3. Restatement of June 30, 2025 financial results
  4. Related party transactions lacking approval
  5. Investment in IGL Genesis Technologies Limited pending approvals
  6. Tax implications of Ebix settlement transaction
  7. Financial information of associate (EIHL) not reviewed by auditor
  8. Financial information of subsidiaries not reviewed by auditor
  9. Ebix Inc. acquisition and settlement, 51% EIHL shares transferred
  10. Restatement of June 30, 2025 standalone financial results
  11. Related party transactions without prior shareholder approval
  12. Investment in IGL Genesis Technologies Limited pending approvals
  13. Tax implications of Ebix settlement transaction under evaluation
  14. Associate and subsidiary financial data not auditor-reviewed

Board Commentary

  1. Related party transactions without shareholder approval
  2. Pending approvals for IGL Genesis investment
  3. Uncertain tax implications of Ebix settlement
  4. Related party transactions require shareholder approval
  5. Pending approvals for IGL Genesis investment
  6. Comprehensive review of compliance requirements
  7. Contribution to Ebix Inc. acquisition

Corporate Governance

  1. Audit Committee reviewed financial results
  2. Related party transactions without shareholder approval

Management Discussion & Analysis

Operational Focus Areas

  1. Evaluating regulatory compliance requirements
  2. Obtaining necessary approvals for transactions
  3. Reviewing business rationale for related party transactions

Risk Control Measures

  1. Evaluating regulatory compliance across jurisdictions
  2. Coordinating with legal and regulatory advisors
  3. Taking appropriate actions for related party transactions

Critical Risks

  1. Related party transactions lacking shareholder approval
  2. Pending approvals for IGL Genesis investment
  3. Uncertain tax implications of Ebix settlement
Dhanarthi

Built With ❤For Indian Investors & Researchers.

With Dhanarthi, stay a step ahead in the market using AI to identify strong stocks and support better financial decisions.

Download AppDhanarthi - AI Driven Stock Insights | Product Hunt

Request an AI Summary of dhanarthi.com

GoogleChatGPTClaudePerplexityGrok

Quick Links

  1. Calculators
  2. Screener
  3. Analysis
  4. Blogs
  5. News
  6. Glossary
  7. Pricing
  8. Contact Us

Stay Ahead with the Financial News & Insights

© 2026 Dhanarthi Research House. All Rights Reserved.

Privacy PolicyTerms & ConditionsDisclaimerCookie Policy

Dhanarthi is an AI-powered stock screening, data analytics, and educational research platform. We are NOT a SEBI-registered investment advisor, research analyst, broker, portfolio manager, or financial institution. All data, screening tools, and financial insights are provided strictly for educational and informational purposes to assist in independent research, and should not be construed as personalized investment advice. We do not offer portfolio management, execution of trades, lending services, or guaranteed returns. Investments in the stock market are subject to market risks. Please consult a qualified financial advisor before making any investment decisions.

Vikas Lifecare Ltd (VIKASLIFE) Quarterly Report Analysis & Insights | Dhanarthi